-
Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition
•
Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive’s evolution as…
-
Vantive Secures Collaborations with Kertone and Qiantang Longyue at CIIE for Dialysis Solutions
•
Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has entered into separate collaboration agreements with the Chinese unit of UK’s Kertone Ltd. and Hangzhou Qiantang Longyue Biotechnology Co., Ltd. at the 7th China International Import Expo (CIIE). These partnerships focus on hemodialysis and peritoneal…
